Tu Dan

Radiation Oncologist/BBQ enthusiast. views my own

[Asal Rahimi M.D., M.S. @AsalRahimiMD]

Grateful to see our Phase I Ablative Preop Single Fraction Radiation Breast Cancer Trial, published in JAMA Network Open.

https://t.co/WxT0t1LUB3

Main Outcome:
30-38Gy ONE fraction pre-op RT led to 72% pCR Rate/ 92% npCR+pCR 🚀

🧵1/4

[Tu Dan @TuDDan]

@NiuSanford Piper NOOO

[Joshua D. Palmer, MD @joshuapalmermd]

Check it out, important data for our brain metastases patients. We get asked a lot following WBRT or SRS, is there a chance for cognitive recovery, we found 38% have CR at 6 months and 68% long term recovery after initial decline. Pooled prospective data.

https://t.co/6JhV1lN2UC

[Tu Dan @TuDDan]

@StasLazarev At the end of the day, most pts will not likely benefit from it, but there does appear to a subset of pts that get meaningful benefit in quality and quantity of life

[Tu Dan @TuDDan]

@StasLazarev Data for gliomas are the most challenging to interpret. Survival curves for RTOG 9802 did not separate until after 4 yrs. Most reasonable people in the field have interpreted the data as reflecting meaningful progress.

[Tu Dan @TuDDan]

@StasLazarev "Seventeen patients received systemic therapy or convection enhanced delivery with omburtamab after initial RT". Need to be well enough to tolerated convection enhanced delivery and live long enough to get reRT (immortal time bias)

[Tu Dan @TuDDan]

@StasLazarev All the points you raise apply to reRT data, should we not offer reRT?

[Tu Dan @TuDDan]

@StasLazarev Figure S6 analyzes by brainstem vs thalamus

[Tu Dan @TuDDan]

@StasLazarev Check column I - 6 of the brainstem pts had not died yet so cannot calculate actuarial survival

[Tu Dan @TuDDan]

@StasLazarev Most centers are doing both onc201 and re-RT, likely both make pts live longer and feel better

[Tu Dan @TuDDan]

@StasLazarev I meant Temodar in GBM - the improvement in median survival not very impressive but the long term survival benefit is where it is most meaningful

[Tu Dan @TuDDan]

@StasLazarev I don't think its reported in the manuscript unfortunately. It was allowed on protocol though. In SIOP pooled analysis of re-RT for DIPG the median OS still in the ~13 month range though. https://t.co/sxOBjANSmi

[Tu Dan @TuDDan]

@StasLazarev Best comparison drug is Temodar - most pts not likely to have huge benefit but significantly increases number of long term survivors. Next step is to identify pts most likely to benefit

[Tu Dan @TuDDan]

@StasLazarev JCO paper excluded DIPG but earlier work from Koschmann group included pediatric DIPG pts showing median OS of ~22 months which compares very favorably to prior COG trials (ie PNOC003 had OS of ~13 months)

https://t.co/hy2YfQ258o

[Dr. Nina Niu Sanford @NiuSanford]

After our daughter Ceci died at 15 mo of a paraspinal tumor, we’ve been committed to supporting pediatric cancer research.

We’re honored this year's Cattle Baron’s Ball will establish Ceci’s Fund through the American Cancer Society.

Please share/donate💕
https://t.co/oOL7q9pyLx

[Prasanna Alluri MD PhD @PrasannaAlluri]

I am excited to share simultaneous publication of two manuscripts from our group in @IJROBP which advance our understanding of radiation-induced cardiac dysfunction.

https://t.co/UW9pVQhSng

https://t.co/5TL8SIqxXo

@UTSW_RadOnc @utswcancer @NewsUtsw16519 @UTSWCancerBio

[Tu Dan @TuDDan]

@AshwinShindeMD @UTSW_RadOnc @MHLinPhD usually we do mr sim with our ct sim for gbm, so instead of mr sim pt had unity sim and mask made while acquiring mr. agree treatment times longer, but most useful application is starting symptomatic pts quicker (essentially just a fancy sim and treat)

[Simon Lo @SimonLo21054188]

Consensus Radiation Treatment Planning Guidelines Utilizing (68)Ga-DOTATATE PET/CT for Resected Meningiomas - International Journal of Radiation Oncology, Biology, Physics- Fantastic work led by ⁦@HaleyPerlow⁩ ⁦@joshuapalmermd⁩ https://t.co/09bBsOa6QS

[Tu Dan @TuDDan]

@BananiSF

[Tu Dan @TuDDan]

Proud to be a part of this project - still have the lab meeting slides from 2018 when we first started. Props to Jong Sun Lee and the rest of @Mendell_lab for the herculean effort of seeing this one to the finish line

[Joshua Mendell @Mendell_lab]

I’m excited to share a pre-print from our lab describing how an ultraconserved long noncoding RNA functions as a unique ribosome assembly factor. This work was led by the talented postdoc Jong-Sun Lee (not on X). Here's a brief 🧵 with the key findings 1/-https://t.co/9l4TX2Xmxp